{"result": "\n{\n    \"title\": \"TRIAL and Multicenter Clinical Studies\",\n    \"summary\": \"The community is centered around the TRIAL, a comprehensive clinical study focusing on critical care, and the MULTICENTER TRIAL, which evaluates interventions for severe conditions like ARDS and septic shock. Key entities include various vasopressor agents, ethical committees, and statistical software used for data analysis. The relationships among these entities highlight the complexity and collaborative nature of these clinical studies.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the significant implications of the clinical trials on critical care treatment strategies and patient outcomes.\",\n    \"findings\": [\n        {\n            \"summary\": \"TRIAL's comprehensive approach to critical care\",\n            \"explanation\": \"The TRIAL is a multifaceted clinical study that addresses several critical care challenges, including ARDS and septic shock. It compares early continuous neuromuscular blockade with usual care, evaluates hydrocortisone versus placebo, and examines different blood transfusion thresholds. The study also assesses the effectiveness of HFOV compared to standard ventilation methods and the impact of various vasopressor agents on patients experiencing shock. This comprehensive approach aims to enhance understanding and improve treatment strategies in critical care settings [Data: Entities (121); Relationships (176, 313, 496, 494, 493, +more)].\"\n        },\n        {\n            \"summary\": \"Role of vasopressor agents in septic shock management\",\n            \"explanation\": \"Vasopressor agents like vasopressin, norepinephrine, and dopamine play a crucial role in managing septic shock, a focus of both the TRIAL and the MULTICENTER TRIAL. Vasopressin was tested as a treatment for septic shock, while norepinephrine is commonly used and compared with vasopressin to evaluate its effectiveness. Dopamine, although used, is associated with higher mortality rates in certain subgroups. These agents are central to the trials' investigations into treating shock by increasing blood pressure [Data: Entities (331, 323, 322); Relationships (178, 179, 146, 496, 494, 493, +more)].\"\n        },\n        {\n            \"summary\": \"Ethical oversight and compliance in clinical trials\",\n            \"explanation\": \"The ethical oversight of the TRIAL and MULTICENTER TRIAL is ensured by various committees, including the ETHICS COMMITTEE and RESEARCH ETHICS BOARDS. These bodies approved the trials at each participating center, ensuring adherence to ethical standards and protocols. The DATA AND SAFETY MONITORING COMMITTEE also plays a vital role in overseeing the conduct of the trials and ensuring participant safety, performing interim analyses to monitor progress and outcomes [Data: Entities (327, 662, 114); Relationships (490, 449, 504, 474, +more)].\"\n        },\n        {\n            \"summary\": \"Statistical analysis and data management\",\n            \"explanation\": \"The trials employ advanced statistical software for data analysis, including SAS Software and SPSS Software. These tools are crucial for performing rigorous statistical analyses, ensuring the reliability and validity of the study findings. The DATA MANAGEMENT COMMITTEE is responsible for analyzing the data collected during the trials, while the EXECUTIVE COMMITTEE oversees the accuracy and completeness of the trial data and analysis [Data: Entities (119, 120, 663, 664); Relationships (481, 483, 450, 1038, +more)].\"\n        },\n        {\n            \"summary\": \"Impact of blood transfusion strategies\",\n            \"explanation\": \"The TRIAL investigates different blood transfusion strategies, comparing outcomes based on higher and lower hemoglobin thresholds. The HIGHER-THRESHOLD GROUP received transfusions at a hemoglobin threshold of 9 g per deciliter, while the LOWER-THRESHOLD GROUP received transfusions at 7 g per deciliter. These strategies are crucial for understanding the optimal transfusion practices in critical care, potentially impacting patient outcomes significantly [Data: Entities (122, 123); Relationships (485, 484, 513, +more)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n121,TRIAL,\"The TRIAL is a comprehensive clinical study encompassing multiple research objectives related to critical care. It includes a comparison of early continuous neuromuscular blockade with usual care in patients suffering from moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). Additionally, the study investigates the effects of hydrocortisone versus a placebo, focusing on critical outcomes such as mortality and the time required for the resolution of shock. Another aspect of the TRIAL involves comparing patient outcomes based on different blood transfusion thresholds. Furthermore, the study evaluates the effectiveness of High-Frequency Oscillatory Ventilation (HFOV) compared to standard ventilation methods. Lastly, the TRIAL examines the impact of various vasopressor agents on patients experiencing shock. Through these diverse research components, the TRIAL aims to enhance understanding and improve treatment strategies in critical care settings.\",40\n103,MULTICENTER TRIAL,\"The \"\"MULTICENTER TRIAL\"\" refers to a clinical study conducted across multiple medical institutions. It is designed to evaluate the effectiveness of cisatracurium in patients with severe Acute Respiratory Distress Syndrome (ARDS). Additionally, this large-scale trial employs stratified randomization to assess various interventions in patients suffering from septic shock. An example of such a multicenter trial is the CORTICUS study, which also involves collaboration among several centers to enhance the reliability and applicability of the research findings.\",16\n331,VASOPRESSIN,\"VASOPRESSIN is a hormone that was the focus of a multicenter, randomized, double-blind trial aimed at evaluating its effect on mortality in patients with septic shock. In this study, vasopressin was administered as a low-dose infusion to manage septic shock and reduce the dosage of norepinephrine. Additionally, vasopressin served as a vasopressor agent used as rescue therapy in the trial.\",13\n323,NOREPINEPHRINE,\"Norepinephrine is a potent α-adrenergic catecholamine vasopressor used in the treatment of shock, particularly septic shock. It is commonly compared with vasopressin in clinical trials for managing septic shock. Norepinephrine is associated with fewer arrhythmic events compared to dopamine, making it a preferred choice in certain clinical scenarios. The use of norepinephrine in these studies follows specific dosing guidelines to ensure efficacy and safety.\",10\n322,DOPAMINE,Dopamine is a vasopressor agent utilized in the treatment of shock. It is associated with an increased incidence of arrhythmic events and higher mortality rates in certain subgroups of patients.,7\n99,SUPPLEMENTARY APPENDIX,\"The \"\"SUPPLEMENTARY APPENDIX\"\" is a comprehensive document that provides additional information and data related to the study and trial. It includes supplementary figures and tables referenced in the main text, as well as detailed statistical analyses and post hoc analyses. The appendix offers further insights into the study's findings by presenting additional methods, patient data, and reasons for patient exclusion. It also contains definitions of ischemic events and a list of board members and guidelines for the study. This document serves as an essential resource for understanding the detailed data and analyses that support the study's conclusions.\",16\n119,SAS SOFTWARE,\"SAS Software is a comprehensive software suite utilized for advanced analytics, business intelligence, data management, and predictive analytics. It is widely recognized as a statistical analysis system, particularly in the context of data analysis for studies. In the specific study referenced, SAS Software, version 9.3, was employed for all statistical analyses, underscoring its pivotal role in facilitating rigorous data examination and interpretation.\",3\n116,TRISS TRIAL,\"A clinical trial investigating transfusion strategies in patients with septic shock, involving randomization and follow-up of patients for 90 days\",6\n122,HIGHER-THRESHOLD GROUP,The HIGHER-THRESHOLD GROUP is a cohort in the trial where patients received blood transfusions at a hemoglobin threshold of 9 g per deciliter. This group of patients was administered more blood transfusions based on this higher hemoglobin threshold.,4\n123,LOWER-THRESHOLD GROUP,The LOWER-THRESHOLD GROUP is a cohort in the trial where patients received blood transfusions at a hemoglobin threshold of 7 g per deciliter.,4\n327,ETHICS COMMITTEE,The ETHICS COMMITTEE approved the trial at each participating center and also approved the protocol for the CORTICUS study at each participating ICU.,2\n329,28 DAYS,The maximum duration of the study period for the trial,1\n230,ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION (APACHE) II,A scoring system used to assess the severity of disease in patients,1\n654,\"DECEMBER 23, 2015\",The date when the trial was completed,1\n330,EPINEPHRINE,Epinephrine is a vasopressor agent used as rescue therapy in the trial,1\n560,FIGURE 1,A figure in the study illustrating the rate of survival and the risk of death at 90 days according to subgroup,1\n561,FIGURE 2,A figure in the study showing the cumulative incidence function of time from randomization to resolution of shock,1\n333,HEMODYNAMIC STABILITY,\"Hemodynamic stability refers to the achievement of a mean arterial pressure of 65 mm Hg, a key goal in the trial\",1\n651,\"JULY 22, 2014\",The date when the trial was suspended for the second time at the request of the data and safety monitoring board,1\n648,\"JUNE 23, 2015\",The date when the last patient was recruited for the trial,1\n650,\"MAY 12, 2012\",The date when the trial resumed after the first suspension,1\n559,MEDICAL-SURGICAL ICUS,\"Intensive care units where the trial was conducted, located in various countries including Australia, the United Kingdom, New Zealand, Saudi Arabia, and Denmark\",1\n653,\"OCTOBER 1, 2014\",The date when the data and safety monitoring board confirmed the trial's conformity to the marketing-authorization application,1\n649,\"OCTOBER 25, 2011\",The date when the trial was first suspended due to the withdrawal of Xigris,1\n652,\"OCTOBER 7, 2014\",The date when the trial resumed after the second suspension,1\n647,\"SEPTEMBER 2, 2008\",The date when the first patient was recruited for the trial,1\n120,SPSS SOFTWARE,SPSS Software is a software package used for statistical analysis,1\n328,WRITTEN INFORMED CONSENT,Consent obtained from patients or next of kin before participating in the trial,1\n332,VASOPRESSOR AGENT,Vasopressor agents are medications used to treat shock by increasing blood pressure,1\n664,EXECUTIVE COMMITTEE,\"The EXECUTIVE COMMITTEE is a pivotal group responsible for overseeing the clinical trial and making critical decisions regarding patient inclusion in the primary analysis. This committee plays a crucial role in ensuring the accuracy and completeness of the trial data and analysis. Furthermore, the EXECUTIVE COMMITTEE is entrusted with the authority to vouch for the integrity of the data and analysis, ultimately making the decision to publish the article.\",5\n663,DATA MANAGEMENT COMMITTEE,The DATA MANAGEMENT COMMITTEE is responsible for analyzing the data collected during the trial by the investigators in the study.,2\n632,LOW-TARGET GROUP,The group in the study targeting a low mean arterial pressure of 65 to 70 mm Hg,2\n662,RESEARCH ETHICS BOARDS,Boards that approved the trial in all participating institutions,1\n315,TABLE S8,A specific table in the Supplementary Appendix that reports findings related to the trial,1\n316,TABLE S9,A specific table in the Supplementary Appendix that presents a breakdown of specific adverse events,1\n326,SHOCK,,4\n217,CANADA,\"Canada was one of the countries where both the study and the trial were conducted, with multiple centers participating in the research efforts.\",2\n681,CARDIAC ARREST,,2\n677,MESENTERIC ISCHEMIA,\"Mesenteric ischemia is a potential adverse effect associated with vasopressin and norepinephrine, involving reduced blood flow to the intestines\",2\n679,SKIN NECROSIS,\"Skin necrosis is a condition involving the death of skin tissue, reported as a side effect of vasopressin and norepinephrine\",2\n680,DIGITAL ISCHEMIA,\"Digital ischemia is a condition involving reduced blood flow to the fingers or toes, reported more frequently in the vasopressin group\",1\n678,HYPONATREMIA,\"Hyponatremia is a condition of low sodium levels in the blood, reported as a side effect of vasopressin\",1\n661,ISRCTN94845869,The Current Controlled Trials number for the vasopressin study,1\n114,DATA AND SAFETY MONITORING COMMITTEE,The DATA AND SAFETY MONITORING COMMITTEE is responsible for overseeing the conduct of the trial and ensuring the safety of the participants. The committee performs interim analysis after 500 patients have been followed for 90 days.,3\n115,COORDINATING CENTER,The COORDINATING CENTER is the entity responsible for monitoring the trial data.,2\n117,INTERNATIONAL CONFERENCE ON HARMONISATION,\"An organization providing guidelines for Good Clinical Practice, which were followed in the statistical analysis of the trial\",1\n197,PROTOCOL COMMITTEE,The committee that wrote the first draft of the manuscript for the trial,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n176,SEPTIC SHOCK,TRIAL,The trial focused on patients with severe septic shock,110\n168,SEPTIC SHOCK,MULTICENTER TRIAL,The trial focused on patients with septic shock,86\n313,ICU,TRIAL,\"The trial, referred to as \"\"TRIAL,\"\" was conducted in the Intensive Care Units (ICU) where patients were treated. It involved monitoring patients in the ICU to gather relevant data and insights.\",86\n178,SEPTIC SHOCK,VASOPRESSIN,Vasopressin was tested and used as a treatment for patients with septic shock in a clinical trial.,83\n179,SEPTIC SHOCK,NOREPINEPHRINE,\"Norepinephrine is commonly used as a treatment for patients with septic shock. In clinical trials, it has been compared with vasopressin to evaluate its effectiveness in managing this critical condition.\",80\n146,SEPTIC SHOCK,DOPAMINE,No significant difference in mortality was observed between dopamine and norepinephrine in patients with septic shock,77\n285,PLACEBO GROUP,TRIAL,The placebo group was a part of the trial,75\n110,PLACEBO,TRIAL,The trial involved administering a placebo to one group of patients,71\n434,SUPPLEMENTARY APPENDIX,EGDT,The Supplementary Appendix contains additional figures and tables related to the study involving EGDT,67\n501,TRIAL,HYDROCORTISONE GROUP,The hydrocortisone group was a part of the trial,62\n201,HYDROCORTISONE,TRIAL,The trial involved administering hydrocortisone to one group of patients,61\n430,SUPPLEMENTARY APPENDIX,TRIAL,\"The Supplementary Appendix contains additional data, figures, and analysis related to the trial, providing further information to support the findings and conclusions of the study.\",56\n482,SAS SOFTWARE,EGDT,SAS software was used to perform statistical analyses for the study involving EGDT,54\n486,TRIAL,CONTROL GROUP,The control group was part of the trial studying ARDS treatment,54\n504,TRIAL,DATA AND SAFETY MONITORING BOARD,The Data and Safety Monitoring Board monitored the trial's safety and data integrity,54\n496,TRIAL,VASOPRESSIN,Vasopressin was used as rescue therapy in the trial,53\n312,ICU,TRISS TRIAL,The ICU was the setting where the TRISS trial interventions and monitoring took place,52\n278,PLACEBO GROUP,SUPPLEMENTARY APPENDIX,The Supplementary Appendix contains additional data and figures related to the placebo group,51\n257,SAS INSTITUTE,TRIAL,SAS Institute provided the statistical software used for the trial's analysis,51\n315,ICU,HIGHER-THRESHOLD GROUP,Patients in the higher-threshold group were monitored in the ICU,50\n314,ICU,LOWER-THRESHOLD GROUP,Patients in the lower-threshold group were monitored in the ICU,50\n494,TRIAL,NOREPINEPHRINE,Norepinephrine was one of the vasopressor agents tested in the trial,50\n265,HOSPITAL,TRIAL,The trial was conducted in a hospital setting where patients were treated,49\n487,TRIAL,INTERVENTION GROUP,The intervention group was part of the trial studying ARDS treatment,48\n60,STEERING COMMITTEE,TRIAL,The steering committee decided to terminate the trial,48\n493,TRIAL,DOPAMINE,Dopamine was one of the vasopressor agents tested in the trial,47\n499,TRIAL,ADVERSE EVENTS,Adverse events were monitored and categorized during the trial,45\n485,TRIAL,HIGHER-THRESHOLD GROUP,The higher-threshold group was one of the two groups compared in the trial,44\n484,TRIAL,LOWER-THRESHOLD GROUP,The lower-threshold group was one of the two groups compared in the trial,44\n481,SAS SOFTWARE,TRIAL,SAS Software was utilized to conduct statistical analyses in the trial.,43\n490,TRIAL,ETHICS COMMITTEE,The ethics committee approved the trial at each participating center,42\n489,TRIAL,O'BRIEN–FLEMING METHOD,The O'Brien–Fleming method was used to determine early stopping criteria in the trial,42\n492,TRIAL,28 DAYS,The trial had a maximum study period of 28 days,41\n488,TRIAL,ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION (APACHE) II,The APACHE II score was used to assess patient severity in the trial,41\n512,TRIAL,\"DECEMBER 23, 2015\",\"The trial was completed on December 23, 2015\",41\n495,TRIAL,EPINEPHRINE,Epinephrine was used as rescue therapy in the trial,41\n502,TRIAL,FIGURE 1,Figure 1 is part of the trial documentation illustrating survival rates,41\n503,TRIAL,FIGURE 2,Figure 2 is part of the trial documentation showing time to resolution of shock,41\n498,TRIAL,HEMODYNAMIC STABILITY,Achieving hemodynamic stability was a key goal in the trial,41\n509,TRIAL,\"JULY 22, 2014\",\"The trial was suspended on July 22, 2014, at the request of the data and safety monitoring board\",41\n506,TRIAL,\"JUNE 23, 2015\",\"The trial completed patient recruitment on June 23, 2015\",41\n508,TRIAL,\"MAY 12, 2012\",\"The trial resumed on May 12, 2012, after the first suspension\",41\n500,TRIAL,MEDICAL-SURGICAL ICUS,The trial was conducted in medical-surgical ICUs across multiple countries,41\n511,TRIAL,\"OCTOBER 1, 2014\",\"The data and safety monitoring board confirmed the trial's conformity on October 1, 2014\",41\n507,TRIAL,\"OCTOBER 25, 2011\",\"The trial was suspended on October 25, 2011, due to the withdrawal of Xigris\",41\n510,TRIAL,\"OCTOBER 7, 2014\",\"The trial resumed on October 7, 2014, after the second suspension\",41\n505,TRIAL,\"SEPTEMBER 2, 2008\",\"The trial began recruiting patients on September 2, 2008\",41\n483,SPSS SOFTWARE,TRIAL,SPSS Software was used to perform statistical analyses in the trial,41\n491,TRIAL,WRITTEN INFORMED CONSENT,Written informed consent was obtained from patients or next of kin for participation in the trial,41\n497,TRIAL,VASOPRESSOR AGENT,Vasopressor agents were central to the trial's investigation into treating shock,41\n192,HYDROCORTISONE,NOREPINEPHRINE,Hydrocortisone was administered to patients who received norepinephrine,31\n432,SUPPLEMENTARY APPENDIX,CONTROL GROUP,The Supplementary Appendix contains additional data on the control group's physiological responses,30\n447,MULTICENTER TRIAL,VASOPRESSIN,The trial was conducted to evaluate the effects of vasopressin on septic shock mortality,29\n381,CISATRACURIUM,MULTICENTER TRIAL,The multicenter trial evaluated the effectiveness of cisatracurium in treating severe ARDS,29\n191,HYDROCORTISONE,DOPAMINE,Hydrocortisone was administered to patients who received dopamine,28\n442,MULTICENTER TRIAL,INVESTIGATORS,Investigators were responsible for conducting and overseeing the multicenter trial,28\n443,MULTICENTER TRIAL,CORTICUS STUDY,The CORTICUS study was conducted as a multicenter trial,28\n448,MULTICENTER TRIAL,NOREPINEPHRINE,The trial was conducted to compare norepinephrine with vasopressin in septic shock treatment,26\n79,AUSTRALIA,VASOPRESSIN,The vasopressin trial was conducted in Australia,26\n429,SUPPLEMENTARY APPENDIX,STUDY GROUP,The Supplementary Appendix contains detailed data and figures related to the study group,25\n431,SUPPLEMENTARY APPENDIX,HFOV GROUP,The Supplementary Appendix contains additional data on the HFOV group's physiological responses,25\n366,NEJM.ORG,SUPPLEMENTARY APPENDIX,The Supplementary Appendix is available with the full text of the article at NEJM.org,24\n239,UNITED STATES,VASOPRESSIN,The vasopressin trial was conducted in the United States,24\n446,MULTICENTER TRIAL,RENAL-REPLACEMENT THERAPY,The trial found a reduced need for renal-replacement therapy in certain patients,23\n806,NOREPINEPHRINE,VASOPRESSIN,\"The trial investigated the effects of vasopressin and norepinephrine on patients with septic shock, specifically focusing on their impact on mortality. Both vasopressin and norepinephrine were compared in this study to determine their efficacy in treating septic shock.\",23\n452,MULTICENTER TRIAL,WRITING COMMITTEE,The writing committee authored the article about the trial,22\n427,SUPPLEMENTARY APPENDIX,TRISS TRIAL,The Supplementary Appendix provided additional data and information for the TRISS trial,22\n433,SUPPLEMENTARY APPENDIX,WRITING COMMITTEE,The Supplementary Appendix contains additional methods and figures related to the study overseen by the writing committee,22\n439,SUPPLEMENTARY APPENDIX,EXECUTIVE COMMITTEE,The Supplementary Appendix contains full details of the trial protocol overseen by the Executive Committee,21\n451,MULTICENTER TRIAL,EXECUTIVE COMMITTEE,The executive committee ensured the accuracy and completeness of the trial data,21\n441,MULTICENTER TRIAL,HIGHER-THRESHOLD GROUP,The higher-threshold group was part of the multicenter trial,20\n440,MULTICENTER TRIAL,LOWER-THRESHOLD GROUP,The lower-threshold group was part of the multicenter trial,20\n444,MULTICENTER TRIAL,HIGH-TARGET GROUP,The multicenter trial included a high-target group targeting a mean arterial pressure of 80 to 85 mm Hg,20\n425,CISATRACURIUM GROUP,SUPPLEMENTARY APPENDIX,The Supplementary Appendix contains additional data and figures related to the cisatracurium group,20\n428,SUPPLEMENTARY APPENDIX,MANAGEMENT COMMITTEE,\"The management committee reviewed study results, and additional details are available in the Supplementary Appendix\",19\n450,MULTICENTER TRIAL,DATA MANAGEMENT COMMITTEE,The data management committee analyzed the data from the trial,18\n445,MULTICENTER TRIAL,LOW-TARGET GROUP,The multicenter trial included a low-target group targeting a mean arterial pressure of 65 to 70 mm Hg,18\n423,EUROPEAN EPIDEMIOLOGIC STUDY,MULTICENTER TRIAL,The European epidemiologic study provided data for the sample-size calculation in the multicenter trial,18\n437,SUPPLEMENTARY APPENDIX,STATA/SE SOFTWARE,Stata/SE software was used to perform the statistical analyses detailed in the Supplementary Appendix,18\n438,SUPPLEMENTARY APPENDIX,AUTHORS,Authors provide additional information in the Supplementary Appendix,18\n801,DOPAMINE,NOREPINEPHRINE,Both dopamine and norepinephrine are used as first-line vasopressor agents in the treatment of shock,17\n227,FRANCE,LOW-TARGET GROUP,The study involving the low-target group was conducted in France,17\n449,MULTICENTER TRIAL,RESEARCH ETHICS BOARDS,The research ethics boards approved the trial,17\n435,SUPPLEMENTARY APPENDIX,TABLE S8,\"Table S8 is part of the Supplementary Appendix, providing additional findings related to the trial\",17\n436,SUPPLEMENTARY APPENDIX,TABLE S9,\"Table S9 is part of the Supplementary Appendix, providing a breakdown of specific adverse events\",17\n816,SHOCK,CONSERVATIVE-STRATEGY GROUP,\"The conservative-strategy group had specific outcomes related to shock, which were compared to those of the liberal-strategy group\",16\n652,CANADA,VASOPRESSIN,The vasopressin trial was conducted in Canada,15\n820,VASOPRESSIN,CARDIAC ARREST,Vasopressin was associated with fewer cardiac arrests compared to norepinephrine in this study,15\n821,VASOPRESSIN,MESENTERIC ISCHEMIA,Vasopressin is associated with the risk of mesenteric ischemia as a side effect,15\n817,SHOCK,LIBERAL-STRATEGY GROUP,\"The liberal-strategy group had specific outcomes related to shock, which were compared to those of the conservative-strategy group\",15\n823,VASOPRESSIN,SKIN NECROSIS,Vasopressin is associated with the risk of skin necrosis as a side effect,15\n824,VASOPRESSIN,DIGITAL ISCHEMIA,Vasopressin is associated with a higher incidence of digital ischemia compared to norepinephrine,14\n818,ETHICS COMMITTEE,CORTICUS STUDY,The ethics committee approved the protocol for the CORTICUS study,14\n822,VASOPRESSIN,HYPONATREMIA,Vasopressin is associated with the risk of hyponatremia as a side effect,14\n819,VASOPRESSIN,ISRCTN94845869,ISRCTN94845869 is the trial number for the vasopressin study,14\n805,NOREPINEPHRINE,SHOCK,Norepinephrine is used as a vasopressor agent in the treatment of shock,14\n39,APACHE II,SAS SOFTWARE,SAS software was used to analyze data including APACHE II scores,14\n473,DATA AND SAFETY MONITORING COMMITTEE,PATIENTS,The Data and Safety Monitoring Committee oversees the safety of the patients during the trial,13\n645,HIGH-FREQUENCY OSCILLATORY VENTILATION (HFOV),CANADA,Canada was one of the countries where the HFOV study was conducted,12\n807,NOREPINEPHRINE,CARDIAC ARREST,Norepinephrine was associated with more cardiac arrests compared to vasopressin in this study,12\n808,NOREPINEPHRINE,MESENTERIC ISCHEMIA,Norepinephrine is associated with the risk of mesenteric ischemia as a side effect,12\n809,NOREPINEPHRINE,SKIN NECROSIS,Norepinephrine is associated with the risk of skin necrosis as a side effect,12\n802,DOPAMINE,SHOCK,Dopamine is used as a vasopressor agent in the treatment of shock,11\n803,DOPAMINE,CARDIOGENIC SHOCK,Dopamine was associated with an increased rate of death in patients with cardiogenic shock,11\n804,DOPAMINE,HYPOVOLEMIC SHOCK,No significant difference in mortality was observed between dopamine and norepinephrine in patients with hypovolemic shock,11\n696,WRITING COMMITTEE,EXECUTIVE COMMITTEE,The Executive Committee made the decision to publish the article written by the Writing Committee,11\n472,DATA AND SAFETY MONITORING COMMITTEE,TRISS TRIAL,The Data and Safety Monitoring Committee oversaw the conduct and safety of the TRISS trial,9\n478,TRISS TRIAL,TRICC TRIAL,The TRICC trial's findings influenced the design and analysis of the TRISS trial,9\n475,COORDINATING CENTER,TRISS TRIAL,The Coordinating Center was responsible for monitoring the data of the TRISS trial,8\n474,DATA AND SAFETY MONITORING COMMITTEE,EXECUTIVE COMMITTEE,The Data and Safety Monitoring Committee worked with the Executive Committee to make decisions about the trial,8\n513,HIGHER-THRESHOLD GROUP,LOWER-THRESHOLD GROUP,Both groups were compared in the trial to assess differences in transfusion thresholds,8\n1038,DATA MANAGEMENT COMMITTEE,EXECUTIVE COMMITTEE,\"The Data Management Committee analyzed the data, and the Executive Committee vouched for its accuracy and completeness\",7\n477,TRISS TRIAL,INTERNATIONAL CONFERENCE ON HARMONISATION,The TRISS trial's statistical analysis was performed according to guidelines from the International Conference on Harmonisation,7\n476,COORDINATING CENTER,PROTOCOL COMMITTEE,\"The coordinating center gathered and analyzed data, while the protocol committee wrote the manuscript\",3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}